Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

About this update from Palvella Therapeutics, Inc.

WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows: Cantor Global Healthcare Conference Thursday, September 4, 2025, at 2:45pm ET H.C. Wainwright 27th Annual Global Investment Conference Monday, September 8, 2025, at 10:30am ET A live webcast of both presentations will be available on the  Events and Presentations  section of Palvella's website at  www.palvellatx.com . An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit  www.palvellatx.com  or follow Palvella on  LinkedIn  or  X  (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication. Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics [email protected] Media Marcy Nanus Managing Partner, Trilon Advisors, LLC [email protected]

View stock analysis, news, and events for Palvella Therapeutics, Inc.